ClinicalTrials.gg
CompletedNCT00083616Updated Jan 10, 2014Results posted

Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

A Phase 2 interventional study of Panitumumab in Colorectal Cancer and Metastatic Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-10.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
22nd of 88
185 · median 70
Started
2004
with 3 others
Phase 2
60 of 90
3 open now
Registered
3rd of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 22nd largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2004, is one of 60 in phase 2, and was the 3rd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.

Read the detailed description

Panitumumab was administered once every 2 weeks until participants developed progressive disease, were unable to tolerate panitumumab, or discontinued treatment for other reasons (eg, administrative decision). Participants then attended a safety follow-up visit 4 weeks from the last panitumumab infusion. Participants were subsequently contacted every 3 months from the last panitumumab infusion through month 24 to assess disease status and survival.

03

Conditions studied

  • Colorectal Cancer
  • Metastatic Cancer

Keywords

  • EGFr
  • Clinical Trial
  • Panitumumab
  • ABX-EGF
  • Immunex
  • Metastatic Cancer
  • Vectibix
  • Abgenix
  • Amgen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue )
  • colorectal carcinoma
  • (ECOG) performance status of 0, 1 or 2
  • Documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer
  • Radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen is required
  • Bidimensionally
  • Tumor expressing epidermal growth factor receptor (EGFr) by immunohistochemistry
  • At least 2 but no more than 3 prior chemotherapy regimens for metastatic colorectal cancer
  • Adequate hematologic, renal and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Symptomatic requiring treatment
  • Patient with a history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis
  • Use of systemic chemotherapy or radiotherapy within 30 days before enrollment
  • Prior epidermal growth factor receptor targeting agents
  • Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short (less than 1 week) serum half-life within 30 days before enrollment, or prior experimental or approved proteins with longer serum half-life (e.g., AvastinTM) within 6 weeks before enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    Panitumumab

    Participants received panitumumab 6 mg/kg once every 2 weeks weeks administered by intravenous (IV) infusion until progressive disease, inability to tolerate the investigational product, or discontinuation of treatment for other reasons.

    Biological: Panitumumab

Interventions

  • BiologicalPanitumumab

    Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.

    Also known as: ABX-EGF, Vectibix

06

What researchers measure

Primary outcomes

  1. Number of Participants With Objective Tumor Response Through Week 16

    Confirmed objective tumor response (complete or partial response) based on modified World Health Organization (WHO) criteria, through week 16. Tumor response was assessed by a central Independent Review Committee (IRC) and confirmation 4 weeks after initial assessment was required. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.

    Time frame: 16 weeks

  2. Duration of Response

    The time from first objective response to first observed progression of disease or death if the death was due to disease progression (whichever comes first); participants who respond and have not progressed while on study or died for reasons other than disease progression while on study were censored at their last evaluable disease assessment date. Response (complete or partial response) was assessed per modified WHO criteria by the central IRC. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.

    Time frame: Until the data cut-off date of 22 December 2006. Maximum time of follow-up was 128 weeks.

Secondary outcomes

  1. Number of Participants With Objective Tumor Response Throughout Study

    Confirmed objective tumor response (complete or partial response) based on modified World Health Organization (WHO) criteria, throughout the duration of the study Tumor response was assessed by a central Independent Review Committee (IRC) and confirmation 4 weeks after initial assessment was required. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.

    Time frame: Until the data cut-off date of 22 December 2006. Maximum time of follow-up was 128 weeks.

  2. Time to Response

    Median time from enrollment to objective tumor response for participants who responded.

    Time frame: Until the data cut-off date of 22 December 2006. Maximum time of follow-up was 128 weeks.

  3. Progression-free Survival Time

    Kaplan-Meier estimate of median time from enrollment to death or first observed disease progression (whichever comes first). Participants who did not progress while on study and did not die while on study were censored at the last evaluable disease assessment date.

    Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.

  4. Time to Disease Progression

    Kaplan-Meier estimate of the median time from enrollment to first observed disease progression or death if death was due to disease progression (whichever comes first). Participants who did not progress while on study or died for reasons other than disease progression while on study were censored at their last evaluable disease assessment date.

    Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.

  5. Time to Treatment Failure

    Kaplan-Meier estimate of median time from enrollment to treatment failure, defined as the date the decision was made to end treatment. Participants remaining in the treatment phase at the time of the analysis were censored on their last visit date.

    Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.

  6. Duration of Stable Disease

    Kaplan-Meier estimates of the median time from enrollment to the date of first observed disease progression or death due to disease progression among those participants with a best outcome of stable disease. Stable disease (SD): Neither sufficient shrinkage of Index lesions to qualify for partial response nor sufficient increase to qualify for progressive disease (PD) taking as reference the nadir sum of the products of the longest diameters (SPD) since the treatment started and the disappearance of or persistence of one or more non-index lesions not qualifying for PD.

    Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.

  7. Overall Survival

    Kaplan-Meier estimate of median time from enrollment to death from any cause. Deaths were recorded during treatment, safety follow-up and long term follow-up.

    Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.

07

Results

Posted Jul 29, 2011

Participant flow

Participants were enrolled from 1 March 2004 through 19 Jul 2006. Patient disposition is reported up until the data cut-off date of 22 December 2006. Completed study is defined as participants who either died on study or completed the safety follow-up visit (30 days after the last dose of panitumumab).

Participant flow — Overall Study
MilestonePanitumumab (ABX-EGF)
Started185
Received study medication182
Completed154
Not completed31
Withdrew: Disease progression16
Withdrew: Lost to follow-up1
Withdrew: Physician decision2
Withdrew: Withdrawal by subject3
Withdrew: Ineligibility determined2
Withdrew: Non-compliance1
Withdrew: Other6

Outcome measures

PrimaryNumber of Participants With Objective Tumor Response Through Week 16

Confirmed objective tumor response (complete or partial response) based on modified World Health Organization (WHO) criteria, through week 16. Tumor response was assessed by a central Independent Review Committee (IRC) and confirmation 4 weeks after initial assessment was required. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.

Time frame:
16 weeks
Reported as:
Number · Participants
Number of Participants With Objective Tumor Response Through Week 16
ParticipantsPanitumumab
Number of Participants With Objective Tumor Response Through Week 165
PrimaryDuration of Response

The time from first objective response to first observed progression of disease or death if the death was due to disease progression (whichever comes first); participants who respond and have not progressed while on study or died for reasons other than disease progression while on study were censored at their last evaluable disease assessment date. Response (complete or partial response) was assessed per modified WHO criteria by the central IRC. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.

Time frame:
Until the data cut-off date of 22 December 2006. Maximum time of follow-up was 128 weeks.
Reported as:
Median · Weeks
Duration of Response
WeeksPanitumumab
Duration of Response14.0 (12.4 to 101.7)
SecondaryNumber of Participants With Objective Tumor Response Throughout Study

Confirmed objective tumor response (complete or partial response) based on modified World Health Organization (WHO) criteria, throughout the duration of the study Tumor response was assessed by a central Independent Review Committee (IRC) and confirmation 4 weeks after initial assessment was required. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.

Time frame:
Until the data cut-off date of 22 December 2006. Maximum time of follow-up was 128 weeks.
Reported as:
Number · Participants
Number of Participants With Objective Tumor Response Throughout Study
ParticipantsPanitumumab
Number of Participants With Objective Tumor Response Throughout Study5
SecondaryTime to Response

Median time from enrollment to objective tumor response for participants who responded.

Time frame:
Until the data cut-off date of 22 December 2006. Maximum time of follow-up was 128 weeks.
Reported as:
Median · Weeks
Time to Response
WeeksPanitumumab
Time to Response11.0 (7.7 to 11.1)
SecondaryProgression-free Survival Time

Kaplan-Meier estimate of median time from enrollment to death or first observed disease progression (whichever comes first). Participants who did not progress while on study and did not die while on study were censored at the last evaluable disease assessment date.

Time frame:
Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Reported as:
Median · Weeks
Progression-free Survival Time
WeeksPanitumumab
Progression-free Survival Time7.3 (7.1 to 7.4)
SecondaryTime to Disease Progression

Kaplan-Meier estimate of the median time from enrollment to first observed disease progression or death if death was due to disease progression (whichever comes first). Participants who did not progress while on study or died for reasons other than disease progression while on study were censored at their last evaluable disease assessment date.

Time frame:
Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Reported as:
Median · Weeks
Time to Disease Progression
WeeksPanitumumab
Time to Disease Progression7.3 (7.1 to 7.6)
SecondaryTime to Treatment Failure

Kaplan-Meier estimate of median time from enrollment to treatment failure, defined as the date the decision was made to end treatment. Participants remaining in the treatment phase at the time of the analysis were censored on their last visit date.

Time frame:
Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Reported as:
Median · Weeks
Time to Treatment Failure
WeeksPanitumumab
Time to Treatment Failure8.0 (7.4 to 8.1)
SecondaryDuration of Stable Disease

Kaplan-Meier estimates of the median time from enrollment to the date of first observed disease progression or death due to disease progression among those participants with a best outcome of stable disease. Stable disease (SD): Neither sufficient shrinkage of Index lesions to qualify for partial response nor sufficient increase to qualify for progressive disease (PD) taking as reference the nadir sum of the products of the longest diameters (SPD) since the treatment started and the disappearance of or persistence of one or more non-index lesions not qualifying for PD.

Time frame:
Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Reported as:
Median · Weeks
Duration of Stable Disease
WeeksPanitumumab
Duration of Stable Disease23.9 (23.0 to 31.0)
SecondaryOverall Survival

Kaplan-Meier estimate of median time from enrollment to death from any cause. Deaths were recorded during treatment, safety follow-up and long term follow-up.

Time frame:
Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Reported as:
Median · months
Overall Survival
monthsPanitumumab
Overall Survival7.0 (5.7 to 8.0)

Adverse events

Collected over From the first dose through maximum of safety follow-up or 30 days after last dose; maximum time on study treatment was 1.25 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab—62/182 (34.1%)176/182 (96.7%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventPanitumumab
DyspnoeaRespiratory, thoracic and mediastinal disorders7/182
Small intestinal obstructionGastrointestinal disorders6/182
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/182
Colon cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/182
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/182
Abdominal painGastrointestinal disorders4/182
Respiratory failureRespiratory, thoracic and mediastinal disorders4/182
Abdominal distensionGastrointestinal disorders3/182
AscitesGastrointestinal disorders3/182
PneumoniaInfections and infestations3/182
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPanitumumab
Dermatitis acneiformSkin and subcutaneous tissue disorders125/182
ErythemaSkin and subcutaneous tissue disorders112/182
PruritusSkin and subcutaneous tissue disorders96/182
FatigueGeneral disorders66/182
NauseaGastrointestinal disorders58/182
DiarrhoeaGastrointestinal disorders48/182
RashSkin and subcutaneous tissue disorders44/182
VomitingGastrointestinal disorders38/182
ConstipationGastrointestinal disorders36/182
Abdominal painGastrointestinal disorders34/182

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panitumumab
Mean59.6 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab
Female85
Male100
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Panitumumab
American Indian or Alaska Native0
Asian4
Black or African American15
Hispanic or Latino19
Japanese0
Native Hawaiian or Other Pacific Islander1
White or Caucasian144
Other2
Aborigine0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Liao MZ, Prenen H, Dutta S, Upreti VV. The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer. Cancer Chemother Pharmacol. 2021 Oct;88(4):665-672. doi: 10.1007/s00280-021-04319-w. Epub 2021 Jul 2. PubMed 34213592 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of May 2007 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2004
First posted
May 28, 2004
Start
Mar 2004
Primary completionActual
May 2007
CompletionActual
Dec 2008
Results first posted
Jul 29, 2011
Last update
Jan 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00083616
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 28, 2004
Start date
Mar 2004
Primary completion
May 2007
Completion
Dec 2008
Results posted
Jul 29, 2011
Last update
Jan 10, 2014

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion